OakChart

CDT Equity Inc

CDTHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 8:44 AM ET

0.5010-0.0603 (-10.74%)
2026-11-11 14:46 CET
Market cap
0.57 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-37.15 USD m
Free cash flow, TTM
-11.48 USD m
EPS diluted, TTM
-2,834,501.10
P/E
-
Compare

Price

CDT against its 20, 50 and 200-day averages
2050200
0.00200,000.00400,000.0013.6M27.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CDTclose 0.5020-day 1.9950-day 62.91200-day 24,269.100.50

100.0% under 372,562.50 on 30 Oct 2025. Last 15 sessions, 594.8% high to low

Profile

CDT
52-week range, 0% of the way up
0.56355,000

CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.

Employees4
IPOMar 28, 2022
Beta1.74
ATR, 14d8.65
Rel volume3.75
Inst own0.06%

Snapshot

6 groups

Valuation

Index-
Market Cap0.51M
Enterprise Value0.94M
Income-37.15M
Sales0.00M
Book/sh81679.82
Cash/sh0.74
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees4
IPOMar 28, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.00
P/C0.68
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.13
Current Ratio0.13
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-2834501.10
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y61.18% -99.07%
Sales past 3/5Y- -
EPS Y/Y TTM98.24%
Sales Y/Y TTM-
EPS Q/Q99.92%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans-
Inst Own0.06%
Inst Trans-
ROA-55.16%
ROE-69.68%
ROIC-36.03%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-74.78%
SMA50-99.20%
SMA200-100.00%
Trades-

Technical

Shs Outstand1.02M
Shs Float-
Short Float-
Short Ratio0.01
Short Interest0.01M
52W High355000.00 -100.00%
52W Low0.56 -10.74%
Volatility32.68% 26.55%
ATR (14)8.65
RSI (14)14.97
Beta1.74
Rel Volume3.75
Avg Volume836.12K
Volume156,936

Performance

Perf Week-50.79%
Perf Month-94.43%
Perf Quarter-99.97%
Perf Half Y-100.00%
Perf YTD-100.00%
Perf Year-100.00%
Perf 3Y-100.00%
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close0.56
Price0.50
Change %-10.74%

Peers

Mkt cap
TickerCompanyMkt cap
BDRXBiodexa Pharmaceuticals Plc ADR1.26M
MTVAMetaVia Inc9.82M
ORMPOramed Pharmaceuticals Inc166.80M
PCSAProcessa Pharmaceuticals Inc5.23M
FBIOFortress Biotech Inc66.03M
TLSATiziana Life Sciences Ltd79.21M
XTLBX.T.L. Biopharmaceuticals Ltd ADR7.64M
RZLTRezolute Inc388.85M
ERNAErnexa Therapeutics Inc3.79M
SCNIScinai Immunotherapeutics Ltd ADR0.66M

News

latest 14 of 99
  • CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo (GlobeNewswire) -10.74%
  • CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides (GlobeNewswire) -11.69%
  • CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch (GlobeNewswire) -14.89%
  • CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset (GlobeNewswire) -46.67%
  • CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery (GlobeNewswire) -23.68%
  • Loading…
  • CDT Equity Inc. Announces Reverse Stock Split (GlobeNewswire) -33.88%
  • CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo (GlobeNewswire) -8.18%
  • CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health (GlobeNewswire) -42.54%
  • CDT Provides Capital Update and Confirms No Nasdaq Deficiencies (GlobeNewswire) -38.51%
  • CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth (GlobeNewswire) -11.90%
  • CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio (GlobeNewswire) -10.11%
  • CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market (GlobeNewswire) -17.67%
  • CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-375000-100680000.101-133800000.134-307965000.308-5889490-2834501.1
Period20212022202320242025TTM
EPS, quarterly-109335000.109-111195000.111-26055000.026-18347700.018-5462680-1645130-1157206.25-27811.2-4353.65
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual000000.001
Period20212022202320242025MRQ
Shares, quarterly00000000.0010.001
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.422.420.460.000.000.00
Gross Profit-2.42-2.42-0.460.000.000.00
Selling, General and Administrative Excl. Other32.4334.3314.965.563.160.00
Research and Development3.365.053.380.090.11-
Other Operating Expense0.000.000.000.000.000.00
Operating Income-34.85-36.76-15.42-5.56-3.16-0.00
Interest Expense0.150.321.510.21--
Unusual Expense1.681.881.18-2.210.27-
Net Income Before Taxes-37.24-39.32-17.80-0.54-4.89-0.00
Income Taxes-0.10-0.100.000.000.000.00
Consolidated Net Income-37.15-39.22-17.80-0.54-4.89-0.00
Net Income From Continuing Operations-37.15-39.22-17.80-0.54-4.89-0.00
Net Income-37.15-39.22-17.80-0.54-4.89-0.00
EPS (Recurring)-33,747.25-5,691,891.89-293,687,943.26-167,907,644.72-96,858,261.23-380,295.14
EPS (Basic, Before Extraordinaries)-2,834,501.10-5,889,490.00-307,965,000.31-11,985,000.01-100,680,000.10-375,000.00
EPS (Diluted)-2,834,501.10-5,889,490.00-307,965,000.31-133,800,000.13-100,680,000.10-375,000.00
EBITDA-32.43-34.33-14.96-5.56-3.16-0.00
Non-Operating Income (Expense)-0.17-0.360.303.03-1.460.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense2.192.181.630.200.00-
Price To Earnings Ratio---648.15648.15-
Shares Outstanding0.000.000.000.000.000.00
Market Capitalization0.570.579.50331.29331.29-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.470.550.520.890.830.200.450.01
Gross Profit-0.47-0.55-0.52-0.89-0.83-0.20-0.45-0.01
Selling, General and Administrative Excl. Other2.533.1120.646.154.123.423.065.81
Research and Development0.300.780.751.531.860.920.133.09
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.00-3.66-21.16-7.03-4.95-3.62-3.51-5.81
Interest Expense0.020.050.040.050.060.180.960.31
Unusual Expense1.520.29-0.270.131.031.44-1.420.39
Net Income Before Taxes-4.64-4.06-21.32-7.21-6.03-4.75-2.41-6.46
Income Taxes0.000.000.00-0.100.000.000.000.00
Consolidated Net Income-4.64-4.06-21.32-7.12-6.03-4.75-2.41-6.46
Net Income From Continuing Operations-4.64-4.06-21.32-7.12-6.03-4.75-2.41-6.46
Net Income-4.64-4.06-21.32-7.12-6.03-4.75-2.41-6.46
EPS (Recurring)-3,358.17-26,421.67-1,167,272.63-1,623,446.86-4,811,189.95-14,467,477.32-36,790,511.27-106,566,265.06
EPS (Basic, Before Extraordinaries)-4,353.65-27,811.20-1,157,206.25-1,645,130.00-5,462,680.00-18,347,700.02-26,055,000.03-111,195,000.11
EPS (Diluted)-4,353.65-27,811.20-1,157,206.25-1,645,130.00-5,462,680.00-18,347,700.02-26,055,000.03-111,195,000.11
EBITDA-2.53-3.11-20.64-6.15-4.12-3.42-3.06-5.81
Non-Operating Income (Expense)-0.11-0.07-0.000.000.010.470.650.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.200.211.580.160.230.360.36
Shares Outstanding0.000.000.000.000.000.000.000.00
Market Capitalization0.5724.082.956.956.617.439.5011.38

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments1.510.554.230.000.05
Short Term Receivables0.000.490.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets2.871.671.500.000.06
Total Current Assets4.382.715.730.000.10
Net Property, Plant & Equipment0.410.300.000.000.00
Total Investments and Advances0.000.000.000.000.00
Intangible Assets--0.000.010.00
Other Assets0.861.181.490.000.11
Total Assets5.654.197.220.010.21
Short Term Debt Incl. Current Port. of LT Debt0.787.350.980.170.18
Accounts Payable1.911.430.000.000.00
Income Tax Payable---0.37-
Other Current Liabilities10.131.960.824.000.02
Total Current Liabilities12.8210.741.804.180.19
Long Term Debt0.000.110.001.830.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.145.884.080.00
Total Liabilities12.8210.997.6810.090.19
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity-7.17-6.79-0.46-10.090.02
Total Shareholders Equity-7.17-6.79-0.46-10.090.02
Accumulated Minority Interest0.000.000.000.000.00
Total Equity-7.17-6.79-0.46-10.090.02
Total Liabilities & Stockholders Equity5.654.197.220.010.21
Book Value Per Share-389,081.83-73,581,022.53-9,284,843.56-207,849,196.541,789,843.75
Tangible Book Value Per Share-389,081.83-73,581,022.53-9,284,843.56-207,952,204.371,789,843.75
Full-Time Employees46733
Price to Book Ratio0.00-1.40-306.46-306.46-
Return on Assets-796.99-311.85-0.74-4,480.92-
Return on Equity---0.810.60-
Return on Invested Capital-----21.25
Quick Ratio0.340.253.180.000.54
Current Ratio0.340.253.180.000.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-37.15-39.22-17.80-0.54-4.89-0.00
Depreciation2.422.420.46---
Other Funds (Non Cash)16.7416.527.80-4.672.020.00
Funds from Operations-17.98-20.28-9.54-5.21-2.86-0.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital6.504.73-0.14-2.520.60-0.01
Income Taxes Payable----0.37-
Cash from Operating Activities-11.48-15.55-9.68-7.72-2.27-0.01
Capital Expenditures-2.00-2.40-0.050.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.010.000.000.00
Purchase of Investments0.000.00-0.490.000.000.00
Sale Or Maturity of Investments0.000.000.500.000.000.00
Other Uses0.000.000.00-0.36-0.330.00
Other Sources1.591.590.001.080.150.00
Cash from Investing Activities-0.40-0.81-0.040.72-0.180.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock8.1119.593.620.150.00-0.02
Repurchase of Common Pref Stock0.00-0.110.000.000.000.00
Sale of Common Pref Stock8.1119.703.620.150.00-0.02
Proceedsfrom Stock Options8.1119.703.330.150.00-0.02
Issuance or Reduction of Debt, Net1.31-2.172.452.291.110.07
Change in Long Term Debt2.160.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt2.160.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.008.491.340.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities9.4117.426.0710.932.450.05
Exchange Rate Effect-0.11-0.10-0.020.300.00-
Net Change in Cash-2.580.95-3.674.230.000.05
Free Cash Flow-11.48-15.96-9.73-7.72-2.27-0.01
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.750.101.514.833.332.13
Short Term Receivables0.170.150.000.400.240.49
Inventories0.000.000.000.000.000.00
Other Current Assets2.022.812.871.872.813.33
Total Current Assets2.943.054.387.096.395.95
Net Property, Plant & Equipment0.220.320.410.520.580.67
Total Investments and Advances122.85122.930.000.000.000.00
Other Assets0.700.780.860.941.021.10
Total Assets126.71127.095.658.557.997.71
Short Term Debt Incl. Current Port. of LT Debt1.180.850.781.872.022.79
Accounts Payable3.732.421.910.611.250.71
Other Current Liabilities18.4418.3710.131.781.141.04
Total Current Liabilities23.3521.6412.824.264.414.55
Long Term Debt0.000.000.000.010.050.08
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.260.000.000.000.000.01
Total Liabilities23.6121.6412.824.274.464.63
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity103.09105.45-7.174.283.533.08
Total Shareholders Equity103.09105.45-7.174.283.533.08
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity103.09105.45-7.174.283.533.08
Total Liabilities & Stockholders Equity126.71127.095.658.557.997.71
Book Value Per Share81,679.82111,648.45-389,081.83418,894.641,474,461.614,856,993.10
Tangible Book Value Per Share81,679.82111,648.45-389,081.83418,894.721,474,459.144,856,971.65
Full-Time Employees--4---
Price to Book Ratio0.000.23-0.411.621.872.41
Return on Assets-55.16-57.17-796.99-351.75-347.94-300.89
Return on Equity-69.68-71.01----
Return on Invested Capital-4.50-3.85--166.08-168.62-150.51
Quick Ratio0.130.140.341.661.451.31
Current Ratio0.130.140.341.661.451.31

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.64-4.06-21.32-7.12-6.03-4.75
Depreciation0.470.550.520.890.830.20
Other Funds (Non Cash)2.231.4810.872.171.641.84
Funds from Operations-1.94-2.04-9.94-4.07-3.56-2.72
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.400.145.30-0.340.98-1.21
Cash from Operating Activities-0.54-1.89-4.64-4.41-2.58-3.93
Capital Expenditures0.000.00-2.000.01-0.00-0.40
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.001.00-1.000.000.00
Purchase of Investments0.000.001.00-1.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.001.590.000.000.00
Cash from Investing Activities0.000.000.59-1.00-0.00-0.40
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.350.001.746.013.788.06
Repurchase of Common Pref Stock0.000.000.000.00-0.110.00
Sale of Common Pref Stock0.350.001.746.013.898.06
Proceedsfrom Stock Options0.350.001.746.013.898.06
Issuance or Reduction of Debt, Net0.830.49-0.00-0.01-0.02-2.13
Change in Long Term Debt0.000.000.002.16-0.02-2.13
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.002.16-0.02-2.13
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.190.491.746.003.765.93
Exchange Rate Effect0.01-0.01-0.03-0.080.03-0.02
Net Change in Cash0.65-1.41-2.330.511.201.58
Free Cash Flow-0.54-1.89-4.64-4.40-2.58-4.33

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.0M-187.38K
2026-10-1525.39%0.0M0.0M29.57K
2026-09-309.32%0.0M0.0M6.85K
2026-09-154.79%0.0M0.0M3.60K
2026-08-310.67%0.0M0.0M1.31K
2026-08-141.42%0.0M0.0M1.44K
2026-07-313.03%0.0M0.0M1.41K
2026-07-15-0.0M-1.41K
2026-06-304.53%0.0M0.0M1.38K
2026-06-152.41%0.0M0.0M185
2026-05-292.47%0.0M0.0M175
2026-05-151.44%0.0M0.0M16
2026-04-301.21%0.0M0.0M18
2026-04-150.78%0.0M0.0M15
2026-03-3192.36%0.0M0.0M10
2026-03-135.41%0.0M0.0M5
2026-02-277.41%0.0M0.0M6
2026-02-135.93%0.0M0.0M4
2026-01-3024.15%0.0M0.0M2
2026-01-155.95%0.0M0.0M2

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09424B3SEC
2026-11-098-KCurrent report2026-11-05SEC
2026-11-06SCHEDULE 13D/ASEC
2026-11-04424B3SEC
2026-11-048-KCurrent report2026-11-02SEC
2026-11-03424B3SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-274/A2026-07-30SEC
2026-10-27SCHEDULE 13D/ASEC
2026-10-273Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-27SEC
2026-10-278-KCurrent report2026-10-22SEC
2026-10-16PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-16SEC
2026-10-13424B3SEC
2026-10-138-KCurrent report2026-10-06SEC
2026-10-08SCHEDULE 13G/ASEC
2026-10-07SCHEDULE 13GSEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-02424B3SEC
2026-09-258-KCurrent report2026-09-24SEC
2026-09-18424B3SEC
2026-09-188-KCurrent report2026-09-14SEC
2026-09-18424B3SEC
2026-09-17EFFECTEffectiveness filing by commission orderSEC
2026-09-09SCHEDULE 13GSEC
2026-09-08S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-09-048-KCurrent report2026-08-31SEC
2026-09-02SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC1.26%
CITADEL ADVISORS LLC0.66%
Virtu Financial LLC0.56%
GEODE CAPITAL MANAGEMENT, LLC0.34%
XTX Topco Ltd0.27%
Financial Management Professionals, Inc.0.21%
Tower Research Capital LLC0.19%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.19%
Fidelity Nasdaq Composite Index Fund0.03%
Fidelity Series Total Market Index Fund0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. CDT. Cached 15 minutes.

Some panels did not load: ratings, insider.